Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: The story mentioned that the cost of this drug treatment was several thousand dollars a month and that this was higher than the costs of other treatments. It would have been better to provide a more concrete estimate of costs (several thousand – does this mean 2,3 or 6 thousand?). The story might have included some information about additional costs that would be encountered with the comparison treatment such as the cost of intraveneous infusions, testing to  evaluate side-effects, and other connected costs. The story did a good job reporting the data comparing patient survival with Iressa as compared to individuals treated with IV chemotherapy. The story skimmed over the side effects; reducing the frequency of bothersome or life threatening side effects would seem to be an advantage. The story mentioned quality of life factors that appear to be better with Iressa but did not  quantify the benefit observed. Borderline satisfactory. The story listed the common side effects of the treatment though it failed to indicate the frequency with which these were seen. In addition, rather than than merely listing these, the story could have included some information about the severity of the side effects (i.e. bothersome vs. fatal). The story provided information about the size of the study conducted, the nature of the patients that were enrolled, and that the drug company that markets the drug funded the study. The study was designed as a non-inferiority survival trial to compare this medication with docotaxel, a chemotherapy treatment often used in individuals who have lung cancer and have had platinum based treatment but who are experiencing a return of their cancer. (While the story did provide information about the survival outcomes, it also included information comparing side effects.) The story ended with a comment from one of the interviewed clinicians about quality of life being better with Iressa. The story should have been clearer about the predetermined endpoint of the study (longevity) and should not have ended with less data driven information. The story did not engage in overt disease mongering. However the headline does not hint that the trial is not about first-line cancer treatment, rather just patients who have been treated previously with a platinum-based chemotherapy. The story included quotes from two individuals identified as not being connected with the study reported upon but with relevant expertise. The story provided information about two treatment options for individuals who have recurrence of a previously treated lung cancer. It did not provide information about the natural history of not undergoing additional treatment for this condition which is necessary for evaluating the relative merit of the two treatments discussed. The story did not mention radiation and surgery which are both options for some limited cancers. The story mentions that the medication Iressa (gefitinib) is sold in the United States but that its availability in Europe is limited. The story presented the use of Iressa as a treatment of individuals with lung cancer who had previously been treated with a platinum-based regimen as though it was a novel application. However – this drug was approved by the FDA in 2003 for this purpose. While the results of study reported on are interesting, the story did not provide the reader with a realistic picture of about the novelty of this product. Does not appear to rely on a press release.
[A]: Pill as good as chemo on lung cancer, but costlier


[Q]: The Hall of Fame rocker, who has been an advocate for teen cancer patients for nearly three decades, visited with children, young adults and their families at Rainbow Babies Hospital on Monday. The Who’s front man toured the Angie Fowler Adolescent & Young Adult Cancer Institute, which was founded in 2012 to better serve young patients while they undergo cancer treatments and following their release. “Teenagers for so long have been overlooked,” said the 73-year-old, still on the road with longtime bandmate Pete Townshend. “Not nearly enough has been done for them.” For years, teenage cancer patients were hospitalized on pediatric floors or placed with older patients. After consulting with doctors researching treatments and recovery, Daltrey understood the need for teens to have a place of their own, where they could recover in surroundings more suited to their interests and maturity level. “The light went on in my head with this one,” said Daltrey, who first got involved with the Teenage Cancer Trust in 1989. “I was in the Who when I was 18 years old and without the support of this age group — adolescents and young adults — our business wouldn’t be there. The music business is built mostly with this age group. It’s an easy way for me to say, ‘Thank you.’” During his visit, Daltrey, whose iconic voice helped make Who songs such as “My Generation,” ″Behind Blue Eyes” and “Won’t Get Fooled Again” anthems for generations of fans, spent time with young cancer patients who have benefited from their time in facilities like the one at Rainbow Babies Hospital. Daltrey quickly connected with several of the teens, who eagerly shared stories of being diagnosed and lengthy hospital stays. He had a warm word, hug or handshake for each of them and was happy to pose for photos. For Adam Kirk, Daltrey’s visit was a chance to meet a rock hero. The 40-year-old’s daughter, Sawyer, has been fighting leukemia for months and Daltrey’s face lit up when he saw the 1½-year-old being carried toward him. Kirk came prepared for his meeting, getting Daltrey to sign a well-worn copy of “Who’s Next,” regarded as the band’s signature album. As he made his way around an outdoor, rooftop garden, Daltrey was approached by another dad who wanted to show his appreciation for the singer’s charitable work. Tyson Stiles presented Daltrey with a musical gift. While his son, Ryver, spent nearly 300 days in the hospital after being born prematurely, Stiles recorded a short album that included songs he wrote about his son’s ordeal. “I wanted you to have a copy,” Stiles said. “Is it any good?” Daltrey asked. “No, it’s terrible,” Stiles quipped as both men laughed. Later, Daltrey donated a guitar signed by him and Townshend that will be permanently displayed in the Fowler Institute’s in-patient unit. Daltrey also shared memories of his previous visits to Cleveland. He and the Who first came to town in 1967. “It’s a lot different than it used to be,” he said. “It was the dirtiest place I’d ever been to in my life. Everything was covered in soot. But Cleveland audiences were some of the best we ever played for.”
[A]: The Who’s Roger Daltrey visits teenage cancer patients.


[Q]: The story makes no mention of costs. With an estimated cost of $150,000 to 200,000, the cost of a allogenic bone marrow transplant is significant enough to be mentioned. We’re giving this one a pass here. The story makes quite clear that it is a report on the experience of only one patient and that while the researchers say there are now no signs of HIV infection in this individual, the tests don’t completely rule out the possibility that the virus is lurking somewhere. In particular, the comments of Dr. Gallo to place the apparent benefit in this single patient into context. The story notes that bone marrow transplants are risky and in fact , “…can kill people.” But it should have told readers that for some types of leukemia, up to 40 percent of patients die have receiving a bone marrow transplant from a donor. What’s more the list of serious complications is harrowing. According to the National Cancer Institute, leukemia patients treated with a bone marrow transplant may have less than a 50-50 chance of successful treatment and even when the treatment works, it is often very painful and may cause serious to kidneys, liver, heart and lungs. So even though this story does tell readers that transplants are risky, it fails to provide numbers that would make clear just how perilous this course of treatment is. The story does a great job on this point, emphasizing the almost unique circumstances of this case and that the results could not be replicated in most people with HIV. By making good use of the right experts, it is able to show what a long shot this treatment really would be for most patients. “AIDS researchers have rejected the approach on any kind of scale for patients with HIV. A bone marrow transplant is a last-ditch treatment for cancers such as leukemia. It requires destruction of a patient’s own bone marrow — itself a harrowing process — and then a transplant from a donor who has a near-exact blood and immune system type. Months of recovery are needed while the transplant grows and reconstitutes the patient’s immune system.” The story does not engage in disease-mongering. The story does point out the staggering number of people worldwide (33 million) infected with the AIDS virus. We would have liked to have seen some mention of the number of people who more closely resemble this patient, having both HIV infection and a type of leukemia that might be treated with a bone marrow transplant. The story’s main expert source was Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS. His comments offered context and appropriate cautions. While the story does not discuss potential conflicts of interest, the researchers declared in their journal article that they had no competing financial interests and the work was supported by non-commercial institutions. The last sentence in the story reads “Cocktails of strong drugs can suppress the virus, keeping patients healthy and reducing the chance they will infect others, but there is no vaccine.” We would have liked to have seen a little more on this point. The fact is, HIV infection is becoming more and more like a chronic disease because of the success of antiretroviral (ARV) therapies. The death rate from AIDS has plummeted, even in developing countries, over the past two decades. This means that, while a vaccine or another therapy that eliminated the virus post-infection would be a boon for humankind, it is not the only approach worth hailing. We would like to see more ink devoted to innovative attempts to stop the spread of HIV and to broadly apply ARVs in countries that already have a high concentration of infected adults and less attention given to one offs like this study. We would have rated this as satisfactory if the story did not mention the vaccine issue. That expands the criterion into prevention and therefore into public health measures as comparators. The story makes it clear that it is based on the findings in one patient and that it couldn’t be applied broadly. The story shows that bone marrow transplants are available and points out the unique aspects of the procedure in this single patient; that is, while bone marrow transplants are available, marrow from recipients with the CCR5 mutation is not. The story apppropriately points out the uniqueness of the report. The patient presented with leukemia and HIV and a donor was available who happened to have te CCR5 mutation. The story did not rely on a news release.
[A]:
German doctors declare “cure” in HIV patient